Visual Indicator Provides Checkpoint to Ensure Protocol Quality
Hercules, CA — October 24, 2012 — Bio-Rad Laboratories, Inc. today announced that proteomics researchers LeeAnn Higgins and Todd Markowski have demonstrated the utility of Bio-Rad’s TGX Stain-Free gels for higher-throughput GeLC-MS analysis. The results, which were presented at the 2012 American Society for Mass Spectrometry (ASMS) annual conference, showed that the stain-free approach has the potential to reduce the sample preparation time of this mass spectrometry workflow from two days to one.
“Our research showed that not only does the stain-free approach work, it can save valuable time without sacrificing the quality of mass spectrometric results,” said Higgins, one of the lead authors of the poster presented at the conference.
GeLC-MS is a modern proteomics workflow widely used for analyzing complex proteomes. The technique involves electrophoretically resolving protein mixtures on an SDS-PAGE gel, staining for visualization, cutting lanes into discrete fractions, processing for in-gel protein digestion, and analyzing the purified peptides by LC-MS/MS.
Previous reports have demonstrated that when compared with in-solution protein digestion and fractionation, GeLC-MS enables more total protein identification and enhances hydrophobic membrane protein identification (Fang et al. 2010; Piersma et al. 2010). However, traditional gel staining methods are time-consuming and laborious, and these drawbacks have limited the adoption of GeLC-MS among proteomics researchers.
Bio-Rad’s TGX Stain-Free precast gels include a unique trihalo compound that enables rapid fluorescent detection of proteins in gels, eliminating the need for gel staining and destaining. For proteomic labs where high throughput is a priority, the stain-free approach conceivably allows researchers to cut protocol times in half. The instant feedback also helps to verify that the protocol is proceeding as intended.
Research Findings
First, the researchers reduced gel electrophoresis times from ~1 hour (using traditional Tris-HCL gels) to 30 minutes with the faster running TGX Stain-Free gels. Next, they eliminated their usual Coomassie Blue staining/destaining steps and used stain-free technology to visualize and cut the protein lanes into discrete fractions. The scientists visualized the proteins in as little as 30 seconds using Bio-Rad’s stain-free enabled imagers (Gel Doc™ EZ and ChemiDoc™ MP). Altogether, these changes saved at least three hours of processing time without causing any losses of protein, peptide, or spectral identifications by mass spectrometry.
“Our research demonstrated that Bio-Rad’s TGX Stain-Free gels improve the speed and ease of processing for the GeLC-MS workflow,” said Markowski, one of the lead authors of the poster. “This knowledge will hopefully enable the wider adoption of GeLC-MS for investigations of complex proteomes.”
For product details or to order TGX Stain-Free gels, visit http://bit.ly/Criterion_SFX.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.
For more information contact:
Marie Nguyen
Bio-Rad Laboratories, Inc.
510-741-5312
marie_nguyen@bio-rad.com
Ken Li
Chempetitive Group
312-997-2436 x 112
kli@chempetitive.com